Threshold Pharma (THLD) – Press Releases
-
Threshold Pharmaceuticals Announces Results of Annual Meeting of Stockholders
-
Threshold Pharmaceuticals Reports Second Quarter Financial Results
-
Threshold Pharmaceuticals Announces First Patient Dosed in Immunotherapy Clinical Trial of Evofosfamide and Ipilimumab
-
OBI Pharma Announces Acquisition of TH-3424 from Threshold Pharmaceuticals
-
Threshold Pharmaceuticals Reports First Quarter Financial Results
-
Threshold Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results
-
Threshold Pharmaceuticals and Molecular Templates Agree to Combine
-
Threshold Pharmaceuticals and National Cancer Institute to Collaborate on Drug Candidate TH-3424
-
Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel Healthcare Conference 2016
-
Threshold Pharmaceuticals Reports Third Quarter Financial Results
-
Caris Life Sciences and Threshold Pharmaceuticals Collaborate to Utilize Caris' ADAPT Biotargeting System in the Development Program for Evofosfamide
-
Threshold Pharmaceuticals Announces Interim Results from Tarloxotinib Program and its Plans to Focus on Evofosfamide and Earlier-Stage Opportunities
-
Threshold Pharmaceuticals Reports Second Quarter Financial Results
-
Threshold Pharmaceuticals Highlights Multiple Presentations at the 2016 ASCO Annual Meeting
-
Threshold Pharmaceuticals to Present at Jefferies 2016 Healthcare Conference
-
Threshold Pharmaceuticals Reports First Quarter Financial Results
-
Threshold Pharmaceuticals Appoints Stew Kroll as Chief Operating Officer
-
Threshold Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Year-End 2015 Financial Results
-
Threshold Pharmaceuticals Announces Presentation and Webcast at the Cowen and Company 36th Annual Health Care Conference
-
Threshold Pharmaceuticals and Merck KGaA, Darmstadt, Germany Agree to Key Terms for the Licensing Back of All Rights to Evofosfamide to Threshold
-
Threshold Pharmaceuticals Announces Workforce Reduction
-
Threshold Pharmaceuticals Announces Its Two Phase 3 Studies Evaluating Evofosfamide Did Not Meet Primary Endpoints
-
Threshold Pharmaceuticals Enters Into Definitive Co-Promotion Agreement for Evofosfamide With Merck KGaA, Darmstadt, Germany
-
Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2015 Healthcare Conference
-
Preclinical Studies Find That Tarloxotinib May Overcome Resistance to EGFR Tyrosine Kinase Inhibitors
-
Threshold Pharmaceuticals Announces Preclinical Data on Combination of Evofosfamide With Immune Checkpoint Inhibitors to Be Presented at the SITC 2015 Meeting
-
Threshold Pharmaceuticals Reports Third Quarter 2015 Financial and Operational Results
-
Threshold Pharmaceuticals Announces Preclinical Data Presentations on Tarloxotinib at the 2015 AACR-NCI-EORTC Meeting
-
Threshold Pharmaceuticals Receives Two U.S. Patents for Tarloxotinib Bromide
-
Threshold Pharmaceuticals Appoints Mark Hopkins, J.D., Ph.D., Vice President of Intellectual Property and Assistant General Counsel
-
Threshold Pharmaceuticals Announces Presentation and Webcast at the Rodman & Renshaw Annual Global Investment Conference
-
Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial of Tarloxotinib Bromide* (TH-4000) in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck or Skin
-
Threshold Pharmaceuticals and ATOMIC Initiate First Phase 2 Clinical Trial of Tarloxotinib Bromide* (TH-4000) in Patients With Advanced EGFR-Mutant, T790M-Negative Non-Small Cell Lung Cancer (NSCLC)
-
Threshold Pharmaceuticals Reports Second Quarter 2015 Financial and Operational Results
-
Rodman & Renshaw 2015 Annual Global Investment Conference to be held in New York from September 8 to 10, 2015
-
Threshold Pharmaceuticals Announces Presentation and Webcast at the Cantor Fitzgerald Healthcare Conference
-
Threshold Pharmaceuticals Presents Encouraging Preliminary Phase 2 Data in Multiple Myeloma at ASCO
-
Threshold Pharmaceuticals Announces Presentation and Webcast at the Jefferies 2015 Healthcare Conference
-
Threshold Announces Clinical Update on Evofosfamide in Relapsed/Refractory Multiple Myeloma to Be Presented at ASCO 2015
-
Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track Designation for Evofosfamide for the Treatment of Patients Living With Advanced Pancreatic Cancer
-
Threshold Pharmaceuticals Announces Presentation and Webcast at the 2015 UBS Global Healthcare Conference
-
Threshold Pharmaceuticals Reports First Quarter 2015 Financial and Operational Results
-
Threshold Pharmaceuticals Reports Preclinical Data Suggesting That TH-4000 May Overcome Resistance to Conventional EGFR Tyrosine Kinase Inhibitors
-
Threshold Pharmaceuticals to Host Analyst and Investor Day on April 24 in New York City
-
Threshold Pharmaceuticals to Present Data Supporting Planned Phase 2 Trials of TH-4000, a Hypoxia-Activated, Irreversible EGFR Tyrosine Kinase Inhibitor
Back to THLD Stock Lookup
